Literature DB >> 33402097

Virtual controls as an alternative to randomized controlled trials for assessing efficacy of interventions.

Joseph M Strayhorn1.   

Abstract

Randomized controlled trials are ubiquitously spoken of as the "gold standard" for testing interventions and establishing causal relations. This article presents evidence for two premises. First: there are often major problems with randomized designs; it is by no means true that the only good design is a randomized design. Second: the method of virtual controls in some circumstances can and should replace randomized designs.Randomized trials can present problems with external validity or generalizability; they can be unethical; they typically involve much time, effort, and expense; their assignments to treatment conditions often can be maintained only for limited time periods; examination of their track record reveals problems with reproducibility on the one hand, and lack of overwhelming superiority to observational methods on the other hand.The method of virtual controls involves ongoing efforts to refine statistical models for prediction of outcomes from measurable variables, under conditions of no treatment or current standard of care. Research participants then join a single-arm study of a new intervention. Each participant's data, together with the formulas previously generated, predict that participant's outcome without the new intervention. These outcomes are the "virtual controls." The actual outcomes with intervention are compared with the virtual control outcomes to estimate effect sizes. Part of the research product is the prediction equations themselves, so that in clinical practice, individual treatment decisions may be aided by quantitative answers to the questions, "What is estimated to happen to this particular patient with and without this treatment?"The method of virtual controls is especially indicated when rapid results are of high priority, when withholding intervention is likely harmful, when adequate data exist for prediction of untreated or standard of care outcomes, when we want to let people choose the treatment they prefer, when tailoring treatment decisions to individuals is desirable, and when real-world clinical information can be harnessed for analysis.

Entities:  

Keywords:  Intervention research; Nonrandomized; Observational; Randomization; Research design; Statistically generated controls; Virtual controls

Mesh:

Year:  2021        PMID: 33402097      PMCID: PMC7783489          DOI: 10.1186/s12874-020-01191-9

Source DB:  PubMed          Journal:  BMC Med Res Methodol        ISSN: 1471-2288            Impact factor:   4.615


  42 in total

1.  Contradicted and initially stronger effects in highly cited clinical research.

Authors:  John P A Ioannidis
Journal:  JAMA       Date:  2005-07-13       Impact factor: 56.272

Review 2.  Effect of a US National Institutes of Health programme of clinical trials on public health and costs.

Authors:  S Claiborne Johnston; John D Rootenberg; Shereen Katrak; Wade S Smith; Jacob S Elkins
Journal:  Lancet       Date:  2006-04-22       Impact factor: 79.321

3.  Blinded trials taken to the test: an analysis of randomized clinical trials that report tests for the success of blinding.

Authors:  A Hróbjartsson; E Forfang; M T Haahr; B Als-Nielsen; S Brorson
Journal:  Int J Epidemiol       Date:  2007-04-17       Impact factor: 7.196

4.  Cognitive-behavior therapy, sertraline, and their combination for children and adolescents with obsessive-compulsive disorder: the Pediatric OCD Treatment Study (POTS) randomized controlled trial.

Authors: 
Journal:  JAMA       Date:  2004-10-27       Impact factor: 56.272

5.  Strengths and Difficulties Questionnaire Added Value Scores: evaluating effectiveness in child mental health interventions.

Authors:  Tamsin Ford; Judy Hutchings; Tracey Bywater; Anna Goodman; Robert Goodman
Journal:  Br J Psychiatry       Date:  2009-06       Impact factor: 9.319

6.  Quasi-experimental study designs series-paper 4: uses and value.

Authors:  Till Bärnighausen; Peter Tugwell; John-Arne Røttingen; Ian Shemilt; Peter Rockers; Pascal Geldsetzer; John Lavis; Jeremy Grimshaw; Karen Daniels; Annette Brown; Jacob Bor; Jeffery Tanner; Arash Rashidian; Mauricio Barreto; Sebastian Vollmer; Rifat Atun
Journal:  J Clin Epidemiol       Date:  2017-03-30       Impact factor: 7.407

Review 7.  Reproducibility of clinical research in critical care: a scoping review.

Authors:  Daniel J Niven; T Jared McCormick; Sharon E Straus; Brenda R Hemmelgarn; Lianne Jeffs; Tavish R M Barnes; Henry T Stelfox
Journal:  BMC Med       Date:  2018-02-21       Impact factor: 8.775

8.  In Vitro and in Silico Evaluation of Bikaverin as a Potent Inhibitor of Human Protein Kinase CK2.

Authors:  Samer Haidar; Dagmar Aichele; Robin Birus; Janine Hielscher; Tuomo Laitinen; Antti Poso; Joachim Jose
Journal:  Molecules       Date:  2019-04-08       Impact factor: 4.411

9.  Recruitment effort and costs from a multi-center randomized controlled trial for treating depression in type 2 diabetes.

Authors:  Barbara A Myers; Yegan Pillay; W Guyton Hornsby; Jay Shubrook; Chandan Saha; Kieren J Mather; Karen Fitzpatrick; Mary de Groot
Journal:  Trials       Date:  2019-11-06       Impact factor: 2.279

10.  Generation of "virtual" control groups for single arm prostate cancer adjuvant trials.

Authors:  Zhenyu Jia; Michael B Lilly; James A Koziol; Xin Chen; Xiao-Qin Xia; Yipeng Wang; Douglas Skarecky; Manuel Sutton; Anne Sawyers; Herbert Ruckle; Philip M Carpenter; Jessica Wang-Rodriguez; Jun Jiang; Mingsen Deng; Cong Pan; Jian-Guo Zhu; Christine E McLaren; Michael J Gurley; Chung Lee; Michael McClelland; Thomas Ahlering; Michael W Kattan; Dan Mercola
Journal:  PLoS One       Date:  2014-01-21       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.